vs
BillionToOne, Inc.（BLLN）与Natera, Inc.（NTRA）财务数据对比。点击上方公司名可切换其他公司
Natera, Inc.的季度营收约是BillionToOne, Inc.的8.0倍（$665.5M vs $83.5M）。Natera, Inc.净利率更高（7.1% vs 6.8%，领先0.3%）。BillionToOne, Inc.同比增速更快（117.4% vs 39.8%）。Natera, Inc.自由现金流更多（$37.8M vs $6.5M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Natera是总部位于美国得克萨斯州奥斯汀的临床基因检测企业，主打无创游离DNA（cfDNA）检测技术，业务覆盖女性健康、肿瘤及器官健康三大核心赛道。其自研专利技术结合前沿分子生物学手段与生物信息学工具矩阵，可实现单管血液样本中低至单个分子级别的高灵敏度检测。
BLLN vs NTRA — 直观对比
营收规模更大
NTRA
是对方的8.0倍
$83.5M
营收增速更快
BLLN
高出77.6%
39.8%
净利率更高
NTRA
高出0.3%
6.8%
自由现金流更多
NTRA
多$31.4M
$6.5M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $665.5M |
| 净利润 | $5.7M | $47.3M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | -3.4% |
| 净利率 | 6.8% | 7.1% |
| 营收同比 | 117.4% | 39.8% |
| 净利润同比 | 138.3% | 187.9% |
| 每股收益（稀释后） | $0.10 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNNTRA
| Q4 25 | — | $665.5M | ||
| Q3 25 | $83.5M | $592.2M | ||
| Q2 25 | — | $546.6M | ||
| Q1 25 | — | $501.8M | ||
| Q4 24 | — | $476.1M | ||
| Q3 24 | $38.4M | $439.8M | ||
| Q2 24 | — | $413.4M | ||
| Q1 24 | — | $367.7M |
净利润BLLNNTRA
| Q4 25 | — | $47.3M | ||
| Q3 25 | $5.7M | $-87.5M | ||
| Q2 25 | — | $-100.9M | ||
| Q1 25 | — | $-66.9M | ||
| Q4 24 | — | $-53.8M | ||
| Q3 24 | $-14.9M | $-31.6M | ||
| Q2 24 | — | $-37.5M | ||
| Q1 24 | — | $-67.6M |
毛利率BLLNNTRA
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNNTRA
| Q4 25 | — | -3.4% | ||
| Q3 25 | 11.5% | -16.5% | ||
| Q2 25 | — | -20.2% | ||
| Q1 25 | — | -15.8% | ||
| Q4 24 | — | -13.6% | ||
| Q3 24 | -32.9% | -8.9% | ||
| Q2 24 | — | -10.6% | ||
| Q1 24 | — | -20.2% |
净利率BLLNNTRA
| Q4 25 | — | 7.1% | ||
| Q3 25 | 6.8% | -14.8% | ||
| Q2 25 | — | -18.5% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -11.3% | ||
| Q3 24 | -38.8% | -7.2% | ||
| Q2 24 | — | -9.1% | ||
| Q1 24 | — | -18.4% |
每股收益（稀释后）BLLNNTRA
| Q4 25 | — | $0.36 | ||
| Q3 25 | $0.10 | $-0.64 | ||
| Q2 25 | — | $-0.74 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.41 | ||
| Q3 24 | $-1.47 | $-0.26 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $-0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | — |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $1.7B |
| 总资产 | $327.5M | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNNTRA
| Q4 25 | — | — | ||
| Q3 25 | $195.2M | $1.0M | ||
| Q2 25 | — | $16.0M | ||
| Q1 25 | — | $17.8M | ||
| Q4 24 | — | $22.7M | ||
| Q3 24 | — | $29.5M | ||
| Q2 24 | — | $90.3M | ||
| Q1 24 | — | $69.1M |
总债务BLLNNTRA
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNNTRA
| Q4 25 | — | $1.7B | ||
| Q3 25 | $-239.5M | $1.3B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $-242.9M | $878.5M | ||
| Q2 24 | — | $836.5M | ||
| Q1 24 | — | $794.1M |
总资产BLLNNTRA
| Q4 25 | — | $2.4B | ||
| Q3 25 | $327.5M | $1.8B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $73.9M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $37.8M |
| 自由现金流率自由现金流/营收 | 7.7% | 5.7% |
| 资本支出强度资本支出/营收 | 8.8% | 5.4% |
| 现金转化率经营现金流/净利润 | 2.42× | 1.56× |
| 过去12个月自由现金流最近4个季度 | — | $109.1M |
8季度趋势，按日历期对齐
经营现金流BLLNNTRA
| Q4 25 | — | $73.9M | ||
| Q3 25 | $13.8M | $59.4M | ||
| Q2 25 | — | $37.6M | ||
| Q1 25 | — | $44.5M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $51.8M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $27.0M |
自由现金流BLLNNTRA
| Q4 25 | — | $37.8M | ||
| Q3 25 | $6.5M | $37.0M | ||
| Q2 25 | — | $11.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.8M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $6.7M |
自由现金流率BLLNNTRA
| Q4 25 | — | 5.7% | ||
| Q3 25 | 7.7% | 6.2% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | — | 8.1% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | 1.8% |
资本支出强度BLLNNTRA
| Q4 25 | — | 5.4% | ||
| Q3 25 | 8.8% | 3.8% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 5.5% |
现金转化率BLLNNTRA
| Q4 25 | — | 1.56× | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
NTRA
暂无分部数据
